Naivek Presents 'KRAS Anticancer Drug' Preclinical Data at American Association for Cancer Research Conference: "90% Tumor Reduction"

[Asia Economy Reporter Hyunseok Yoo] Naivek, a peptide fusion specialist company, announced on the 20th that it has been invited to the American Association for Cancer Research (AACR) special conference, the 'RAS Targeting Conference,' to present preclinical research results related to KRAS-targeting anticancer drugs.

The AACR Targeting RAS conference is scheduled to be held in Florida, USA, from January 7 to 10 next year. Naivek was selected to present the preclinical topline research results and plans to conduct partnering meetings following the presentation of the research findings.

At this conference, Naivek will present preclinical research results of the KRAS-targeting anticancer drug ‘NIPEP-TPP-KRAS.’ NIPEP-TPP-KRAS is being co-researched with Seoul National University and is based on the drug delivery platform ‘NIPEP-TPP,’ which has selective targeting functions and cell and tissue penetration capabilities. Research results on PROTACs, which conjugate antibodies and gene delivery agents to completely degrade and eliminate disease-causing proteins, will also be presented.

KRAS is recognized as the most dangerous mutation for cancer cell proliferation because it sends signals that regulate cell growth among the RAS genes involved in human tumor formation. Naivek is gaining significant attention in the market as a frontrunner in KRAS anticancer drugs, capable of selectively targeting only mutated KRAS.

Naivek is conducting research on various cancer types, including lung cancer, colorectal cancer, and prostate cancer, targeting mutated KRAS. It was the first in the world to introduce gene drug delivery agents and has verified efficacy in anticancer treatment through a syngeneic colorectal cancer animal model.

Naivek’s antibody pipeline has already clearly confirmed the 'tumor treatment mechanism.' In mouse experiments inducing lung cancer (syngeneic animal model), tumor size was reduced by 90% compared to untreated groups, and life was extended by about 40 days, demonstrating excellent efficacy. Recently, GLP toxicity tests related to this have been underway.

A Naivek official stated, “KRAS-targeting anticancer drugs are not behind in development stages compared to global developers, attracting interest from global big pharma, and we are continuing technical discussions related to this. Through this special conference, we plan to meet with leading researchers and corporate representatives in the RAS field, and we expect to achieve meaningful results as an opportunity to externally showcase Naivek’s technological capabilities.”